BiotechTube
Sairopa

Sairopa

Rotterdam, Netherlands· Est.
sairopa.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $12.5M

Overview

Sairopa is a private, clinical-stage biotech company developing next-generation immunotherapies to address the limitations of current checkpoint inhibitors, which benefit only about 30% of cancer patients. Its core assets include ADU-1805 (anti-SIRPalpha) and ADU-1604 (anti-CTLA-4), acquired from Chinook Therapeutics and originally derived from the B-Select antibody platform used for Keytruda. The company is led by a small, experienced team with strong ties to Dutch life sciences investment firm Van Herk Investments and is currently advancing its lead candidate, ADU-1604, in Phase 1 clinical trials for advanced melanoma.

Oncology

Technology Platform

Assets derived from the B-Select antibody platform, a human antibody discovery platform previously used to identify pembrolizumab (Keytruda).

Funding History

2
Total raised:$12.5M
Series A$10M
Seed$2.5M

Opportunities

The primary opportunity is addressing the ~70% of cancer patients unresponsive to first-generation checkpoint inhibitors by modulating earlier steps in the cancer-immunity cycle.
Success with its next-gen CTLA-4 or SIRPalpha antibodies could position them as valuable components in combination therapy regimens, a dominant trend in oncology.

Risk Factors

High clinical development risk as lead candidate ADU-1604 is in early Phase 1.
The company faces significant financing risk as a small, private, pre-revenue entity.
Intense competition in immuno-oncology from larger, well-funded players poses a threat to differentiation and market entry.

Competitive Landscape

Sairopa competes in the crowded next-generation immuno-oncology space. For ADU-1604, competitors include other companies developing improved anti-CTLA-4 antibodies (e.g., Agenus, BioNTech). For ADU-1805, it faces numerous biopharma firms targeting the CD47-SIRPalpha axis, such as Gilead (magrolimab), ALX Oncology, and Trillium Therapeutics (now Pfizer).

More companies in Biologics / Biosimilars →More companies in Netherlands →